Health-related quality of life in multiple myeloma patients treated with high- or low-dose lenalidomide maintenance therapy after autologous stem cell transplantation: results from the LenaMain trial (NCT00891384)
Introduction: The LenaMain trial (NCT00891384) reported increased progression-free survival with 25 mg of lenalidomide maintenance compared to 5 mg. Here, we report the patient-reported outcomes. Materials and Methods: Scores obtained from the EORTC Quality of Life Questionnaire C30 were analyzed fo...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
26 October 2023
|
| In: |
Cancers
Year: 2023, Volume: 15, Issue: 21, Pages: 1-17 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers15215157 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers15215157 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/15/21/5157 
|
| Author Notes: | Amelie Boquoi, Aristoteles Giagounidis, Hartmut Goldschmidt, Michael Heinsch, Mathias J. Rummel, Nicolaus Kröger, Elias K. Mai, Judith Strapatsas, Rainer Haas and Guido Kobbe |
| Summary: | Introduction: The LenaMain trial (NCT00891384) reported increased progression-free survival with 25 mg of lenalidomide maintenance compared to 5 mg. Here, we report the patient-reported outcomes. Materials and Methods: Scores obtained from the EORTC Quality of Life Questionnaire C30 were analyzed for longitudinal changes from baseline within the groups as well as cross-sectional scores. Results: Compliance rates were high, with 95.7% at baseline and 70% during maintenance. At study entry, scores were high for functioning and low for symptoms. During maintenance, the median global health status/quality of life (GHS/QoL) was constant, without significant differences over time (median GHS/QoL: 68 at baseline and 58 for Len high and 68 for Len low at 2 years) and between treatment arms (mean change < 2). Similarly, most functional scale domains were constant. Notably, diarrhea increased consistently for both treatment arms (baseline: −1.905 (range: −5.78-1.97); end of year 2: 16.071 (range: 5.72-26.42); p < 0.05). The subgroup analysis showed that neither disease activity, duration of treatment, nor adverse events affected the health-related quality of life (HR-QoL) or utility. Conclusion: High baseline scores were maintained throughout the trial without significant differences between the Len dosages, which supports continuous treatment with a dose tailored to patients’ HR-QoL. |
|---|---|
| Item Description: | Gesehen am 17.05.2024 |
| Physical Description: | Online Resource |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers15215157 |